CATL Shares Fall as Hungary Plant Faces Safety Halt 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Milei Threatens Falkland Oil Firms With Sanctions 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
France Targets Shein, Temu With Fast-Fashion Fees 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Add as a preferred source on Google
RANCHO CORDOVA, Calif., March 06, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) today announced that Joe Balagot, senior vice president of corporate development, will present an overview of the company, with a focus on its automated, closed systems for manufacturing CAR-T and other cell therapies, at the BIO-Europe Spring 12th Annual International Partnering Conference, which is being held March 12-14 at the Amsterdam RAI Convention Center in Amsterdam, The Netherlands.
Mr. Balagot’s presentation is scheduled to take place on Tuesday, March 13 at 3:30pm CET in Room E106.
With a focus on European innovation and global collaboration, BIO-Europe Spring 2018 is the premier springtime partnering conference bringing together executives from biotech, pharma and finance in the most innovative biopharma clusters in Europe. For more information about the conference, go to: https://ebdgroup.knect365.com/bioeurope-spring/
About Cesca Therapeutics Inc.
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected]
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]
